Member Info for crumbs

Ivy, there is no reason DNA can't do an mRNA... I think the main stumbling block being delivery we already know electroporation which Lindy also chose out of other options at the time and turned out a good choice as well it works!... practically it is not ideal least not for worldwide viral pandemics .... sorry Inovio :) ... However progress has been made and now Lindy is going with what turns out to be a local potential solution the Notts nano peptide delivery.. throw in AvidiMab for good measure and well.... All the talk of mRNA and banks of mRNA vaccines against all viruses etc could well become mRNA and DNA.... but you only get little windows of opportunity I think we were somewhat cheated somehow from SCIB1 trial success... but gosh what a chance there is now... and with the landgrab of the moditope way too... plus of course now AvidiMab and the glycans... but why can't we just get anything over that final line!

Boom certainly I trust in Lindy and her decisions.. she does the science I mean she really does :) there isn't an angle she does not look at I reckon gratingly these things take time... in theory, though the time to progress all that benchwork forwards is now the pre-clinical graft has been done so time to trial ....

of course, mRNA now is a buzz and will attract big money and attention same story Checkpoint inhibitors we saw it happen before Lindy has chosen her paths forwards here and they could prove to be the most valuable the time is now though lol... as we all know redmiles /Vulpes millions only go so far and then what.

Our old chums BioNTech

'Ugur Sahin: : We have been working on mRNA for more than 20 years. The reason why we started was our vision of individualised cancer therapy, based on the observation that the tumour antigens, the antigens on cancer cells, which are recognised by T cells (in the immune system), are unique in every cancer patient.

We understood that a future therapy could be (based on) analysing the patient tumour and finding out which antigens would be suitable and then producing a vaccine based on this information. And this idea requires the right technology – a technology which would allow (us) to induce an immune response against any type of tumour antigen in a potent way and which can be manufactured within a few weeks – because the cancer, of course, might be growing.

When we started, we evaluated DNA, vector-based vaccines, peptides, recombinant proteins – everything that has been tested before as a potential vaccine technology. But then we evaluated mRNA and we understood this could be really powerful. We could see that mRNA could be expressed in dendritic cells, which are the key cells for inducing an immune response. And that was one decisive factor and the ability to manufacture the vaccine fast was another. And that's why we started to develop mRNA vaccines.'
https://horizon-magazine.eu/article/qa-biontech-vaccine-only-mrna-10-just-beginning-say-co-founders.html

Lindy chose DNA over mRNA
'. In the case of ImmunoBody®, the DNA form is taken up and processed directly by dendritic cells whereas the protein form (which is produced from the DNA in cells at the site of the injection) binds to the high affinity Fc receptor on dendritic cells leading to cross-presentation. As a result of both the direct and cross-presentation, the T cells not only have a higher avidity (up to 100-fold increased potency), but there are many more T cells generated against the epitopes of interest.'

WTP.... Goobers lol

'Testing the quickly designed vaccines required a monumental effort by companies and the National Institutes of Health. But Dr. Kariko had no doubts.

On Nov. 8, the first results of the Pfizer-BioNTech study came in, showing that the mRNA vaccine offered powerful immunity to the new virus. Dr. Kariko turned to her husband. “Oh, it works,” she said. “I thought so.”

To celebrate, she ate an entire box of Goobers chocolate-covered peanuts. By herself.

Dr. Weissman celebrated with his family, ordering takeout dinner from an Italian restaurant, “with wine,” he said. Deep down, he was awed.

“My dream was always that we develop something in the lab that helps people,” Dr. Weissman said. “I’ve satisfied my life’s dream.”

Well I guess scancell have a little time yet with current timelines but we are really at the cusp there now...h1 is when its all supposed to happen after all! modi1 SCIB1 combo (the trial that has really caused the bad feeling towardsgiven timelines that one) And of course the Covidity 'in weeks' that was weeks ago... anyways h1 is where we are at but it is being eaten away... I doubt redmile will sit back and allow timelines to slip in the way they have previously they surely have a 2 year plan to get at an mcap in billions and hit the NASDAQ,maybe :)
Anyways newsflow now must come ... If scancell have gone with COBRAs premium service which I guess they will have then they manufacture in 6 weeks I think so I reckon by now those plasmids will be manufactured tested etc ... ready for trial!....There could well be issues between team science and team commercial at scancell obviously one gets the most say but we need deal/s done...like I say at the cusp now

Only 2 mRNA products in the world approved one for BioNTech one for Moderna .. the first 2 companies who many years ago saw in it its vaccine potential due to the work of Dr. Weissman and Dr. Kariko.....

Both those companies did get, well compared to scancell , enormous backing and support from the get go....
their worths today....BioNTech a whopping $29.5 billion... Moderna an incredible $56.4 billion.... And no I don't know why Moderna is worth twice as much as BioNTech?... markets huh but
shows the risk/reward here means the potential rewards if all goes as it could are fall off your stool then jump to the ceiling amazing... well if we ever hit a timeline and actually get an approved product :)

Nomlungu I think

“This has been a coming-out party for mRNA, for sure,” John Mascola, director of the Vaccine Research Center at NIAID, told The Atlantic. “In the world of science, RNA technology could be the biggest story of the year. We didn’t know if it worked. And now we do.”

But before we turn the corner on a new age of drug development, it’s worth remembering that it took 40+ years to get this far for two products.'
https://www.biospace.com/article/the-mrna-revolution-is-here-and-it-took-about-50-years/

It came with a scancell timeline !:)

Another worthwhile read that.... As for scancell potential values indeed the science needs proving up but there is rather a lot of it Lindy has been spending her life building scancell IP and nothing of it has really been valued but I think like the checkpoint inhibitors story the mRNA one is interesting and relevant as to potential here... and yeah scancell can possibly eclipse both and with no need for patent battles :) I'm not putting a figure on it but would like to think we get a real idea withing the next 2 years... then we can maybe look at figures

Usually, I'd recommend this as a Sunday read ... but seeing as I don't think it will be Friday night fight night this week... I recommend this fantastic read ...
https://www.nytimes.com/2021/04/08/health/coronavirus-mrna-kariko.html

'“We both started writing grants,” Dr. Weissman said. “We didn’t get most of them. People were not interested in mRNA. The people who reviewed the grants said mRNA will not be a good therapeutic, so don’t bother.’”

Leading scientific journals rejected their work. When the research finally was published, in Immunity, it got little attention.

Dr. Weissman and Dr. Kariko then showed they could induce an animal — a monkey — to make a protein they had selected. In this case, they injected monkeys with mRNA for erythropoietin, a protein that stimulates the body to make red blood cells. The animals’ red blood cell counts soared.

The scientists thought the same method could be used to prompt the body to make any protein drug, like insulin or other hormones or some of the new diabetes drugs. Crucially, mRNA also could be used to make vaccines unlike any seen before.'

Wonder how much mRNA is worth now?..... I'm not underestimating the potential values of Lindys patents.....

Freedom of speech v cancel culture....v topical :-)
Usually find people support freedom of speech when it's their own views being spoken and no one likes cancel culture until they want an opposing view shut up...and even a bit punished

Surely it is more a pastime than occupation :)
BB chat here has become as glitchy as a really glitchy thing though and wish they would sort it... probably a case of trying to fix something that was not broken... and breaking it!

This pandemic is going to go on and on with all that comes with it at least that is the picture painted from this article authored by 'experts'.... still one thing is for sure now is the time to be in the vax business especially if you can produce effective ones.
https://www.abc.net.au/news/2021-04-06/coronavirus-variants-mean-vaccination-cant-control-pandemic/100049682

BTW theirs is another sp to watch... 2 euros to 15 in a year....

Come on Notts team lets not let Spring trial start become summer!

https://uk.finance.yahoo.com/news/valneva-reports-positive-phase-1-050000449.html
VLA2001 induced broad T-cell responses across participants with antigen-specific IFN-gamma producing T-cells against the S-protein, M and N protein detected in 75.6 %, 35.6% and 48.9% of study participants, respectively.

Thomas Lingelbach, Chief Executive Officer of Valneva, said: “We are extremely pleased with these results which take us a step closer to providing an inactivated vaccine to help the global fight against COVID-19. The world needs multiple vaccines as well as booster options. Given the potential advantages often associated with inactivated whole virus vaccines, we believe that VLA2001 has an important role to play. This includes potential modifications to the vaccine to address variants, using our existing manufacturing process. I want to thank everyone involved in the ongoing work. We could not have achieved this milestone without them.”

Health and Social Care Secretary, Matt Han**** said: “The U.K. government has funded these clinical trials and it is fantastic to see Valneva’s vaccine produces a strong immune response. This vaccine will be made onshore in Livingston in Scotland, giving another boost to British life science, and if approved will play an important role in protecting our communities. I look forward to seeing the results of the upcoming phase 3 trial.”

Vaccines Minister Nadhim Zahawi said: “These results are very promising and provide renewed hope that a vaccine using a whole inactivated virus might provide strong protection against variants. If the results from the phase 3 clinical trials are positive and the vaccine meets the robust standards of safety, quality and effectiveness of our medicines regulator, the MHRA, this will be another powerful weapon in our arsenal to beat this pandemic. The government has funded the clinical trials for this promising vaccine and, if approved, it will be manufactured in Scotland, boosting the UK’s ability to become more self-sufficient in the future.”

No, if Vulpes bought more it would not alter redmiles % unless more shares were issued for Vulpes to buy.... it ain't going to happen and if anything Vulpes is now a seller of shares and their % goes down...

It is also the biggest and best prop! :)

Going off CH's last presentation it sounds to me there will be a dip into redmile funding to progress Covidity.....that ph1 ain't going to be cheap

CEPI fund at ALL stages....

the only scancell related part though:)

'Alternative strategies to target DCs include fusion strategies based on IgG scaffolds that introduce antigen epitopes in the CDR region and vaccine delivery using a DNA based vector system with the aim to target the high affinity FcgRI (222, 223). The goal and advantage of these technologies is to provide a single drug entity which can harness both the adjuvant and targeting of the antigen to APCs, as well as the potential antigen half-life extension that the methodology provides. It also ensures that HLA/peptide off-rate is not the determining factor for antigen delivery to the lymph node.'

Part of the series scancells article is included in.... some other familiar names:
https://www.frontiersin.org/articles/10.3389/fimmu.2020.615240/full

Again the CEPI situ is not the same as GC I think ray did a great post about that.... and simply we do not even know if scancell have approached or otherwise CEPI whereas GC we knew we were in a final and there would be a results day... so if people want to get overly excited by CEPI prospects (which I think are real) and they get disappointed on nothing coming from it then that is their issue lol.. I just take the view of an observer looking at it all unfold and see no harm in speculating on all angles I like to think we all here are mature enough for that :)
BTWcCovidity is not a platform but a product of one, one that it could alone make that platform very very valuable and of great interest to pharma... something sadly SCIB1 failed at despite being a success... Again nothing wrong in looking at all funding options current and future and what may drive them.. at the moment we are ok but as you say that will change as the money is spent... if we are getting in great data I do not see there will be much of an issue .... if it gets a bit more messy well then... still that is why on risk/reward the risk is still very real and the reward potential keeps on getting bigger!

Happu Easter all and let us hope we are now at the beginning of our world-changing journey.... get them trial going already!